BioLife Solutions, Inc.
18.50%
8,735,159
834365
09062W204
Apr 6, 2025
Apr 9, 2025, 05:13 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Casdin Capital, LLC | Investment Adviser | 18.50% | 8,735,159 | 0 | 8,735,159 |
| Casdin Partners Master Fund, L.P. | Partnership | 18.50% | 8,735,159 | 0 | 8,735,159 |
| Casdin Partners GP, LLC | Other | 18.50% | 8,735,159 | 0 | 8,735,159 |
| Eli Casdin | Individual | 18.50% | 8,735,159 | 0 | 8,735,159 |
Disclosure Items (7)
Common Stock, $0.001 par value
BioLife Solutions, Inc.
3303 Monte Villa Parkway, Bothell, WA, 98021
(a), (f) This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company ("Casdin"), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), Casdin Partners GP, LLC, a Delaware limited liability company (the "GP") and Eli Casdin, a United States citizen (collectively, the "Reporting Persons").
The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019.
Eli Casdin is the managing member of Casdin and the GP. The principal business of Casdin is serving as an investment adviser to its clients. The principal business of the GP is serving as the general partner to certain private funds. Casdin is the investment manager to the Fund and the GP is the general partner of the Fund. The principal business of the Fund is purchasing, holding and selling securities for investment purposes.
The funds for the purchase of the Shares by the Fund came from the working capital of the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion. No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.
(a) - (e) As of the date hereof, Casdin, the Fund, the GP and Eli Casdin may be deemed to be the beneficial owners of 8,735,159 Shares, constituting 18.5% of the Shares based upon 47,241,355* Shares outstanding. Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 8,735,159 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 8,735,159 Shares. The Fund has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 8,735,159 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 8,735,159 Shares. The GP has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 8,735,159 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 8,735,159 Shares. Eli Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 8,735,159 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 8,735,159 Shares. The transactions by the Reporting Persons in the Shares are set forth in Exhibit B. *This outstanding Shares figure reflects the number of outstanding Shares at April 7, 2025.
Not Applicable.
Exhibit A: Joint Filing Agreement Exhibit B: Schedule of Transactions in Shares